Goldman Sachs Maintains Buy on Viridian Therapeutics, Raises Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Richard Law has maintained a Buy rating on Viridian Therapeutics and increased the price target from $25 to $31.
September 12, 2024 | 3:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs has reaffirmed its Buy rating on Viridian Therapeutics and increased the price target from $25 to $31, indicating confidence in the company's future performance.
The increase in price target from $25 to $31 by a reputable firm like Goldman Sachs suggests a positive outlook for Viridian Therapeutics. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100